Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

A new drug by pharmaceutical giant Eli Lilly rivaling Ozempic and Wegovy could lead to 'significantly' more weight loss after ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Eli Lilly (LLY) stock rises as analysts cheer Phase 3 trial data for the company's next-gen weight loss therapy, retatrutide.

Some patients dropped out of the trial early because they had lost so much weight.